Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.76 USD | +0.86% | +3.00% | -22.60% |
03-26 | Surgery Partners Unit to Offer $600 Million of Senior Notes | MT |
03-06 | Surgery Partners Insider Sold Shares Worth $277,633, According to a Recent SEC Filing | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm trades with high earnings multiples: 27.13 times its 2024 earnings per share.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.60% | 3.1B | C- | ||
-17.07% | 16.21B | B+ | ||
+3.60% | 12.44B | B | ||
+5.64% | 11.58B | B+ | ||
+4.63% | 10.79B | B+ | ||
+25.36% | 8.26B | B | ||
-0.76% | 7.68B | A- | ||
+22.18% | 7.06B | D | ||
+5.77% | 6.67B | B- | ||
+52.00% | 4.66B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SGRY Stock
- Ratings Surgery Partners, Inc.